Laurion Capital Management’s Cardiff Oncology CRDF Stock Holding History

Laurion Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.03M	Buy	3,098,299 +451,561	+17%	+$717K	0.1%	164
2026 Q1	$4.29M	Hold	2,646,738	–	–	0.19%	146
2025 Q4	$7.44M	Buy	2,646,738 +180,866	+7%	+$420K	0.28%	65
2025 Q3	$5.08M	Buy	2,465,872 +668,590	+37%	+$1.85M	0.09%	128
2025 Q2	$5.66M	Buy	1,797,282 +881,068	+96%	+$2.69M	0.1%	130
2025 Q1	$2.88M	Buy	916,214 +339,290	+59%	+$1.34M	0.07%	132
2024 Q4	$2.5M	Buy	+576,924	New	+$1.8M	0.05%	178
2024 Q2	–	Sell	-928,717	Closed	-$4.96M	–	598
2024 Q1	$4.96M	Buy	928,717 +206,617	+29%	+$549K	0.04%	256
2023 Q4	$1.07M	Hold	722,100	–	–	0.01%	336
2023 Q3	$1M	Hold	722,100	–	–	0.01%	368
2023 Q2	$1.06M	Hold	722,100	–	–	0.01%	363
2023 Q1	$1.19M	Hold	722,100	–	–	0.01%	297
2022 Q4	$1.01M	Hold	722,100	–	–	﹤0.01%	335
2022 Q3	$1.11M	Hold	722,100	–	–	0.01%	364
2022 Q2	$1.59M	Buy	+722,100	New	+$1.21M	0.02%	247

Other funds holding CRDF

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Laurion Capital Management's CRDF Position: Q2 2026 in Review

Laurion Capital Management increased its Cardiff Oncology (CRDF) stake by 17% in Q2 2026, buying an estimated $717K and bringing the position to 3,098,299 shares worth $4.03M. The position accounts for 0.1% of the portfolio, ranked #164.

Laurion Capital Management first reported a position in CRDF in Q2 2022 and has held it in 15 quarters since. The position peaked at $7.44M in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Laurion Capital Management held 3,098,299 shares of Cardiff Oncology worth $4.03M as of Q2 2026.
Laurion Capital Management bought 451,561 Cardiff Oncology shares in Q2 2026, an estimated $717K.
Cardiff Oncology made up 0.1% of Laurion Capital Management's portfolio in Q2 2026, its #164 holding.
Laurion Capital Management first reported a position in Cardiff Oncology in Q2 2022 and has held it in 15 quarters since.
Laurion Capital Management's Cardiff Oncology position peaked at $7.44M in Q4 2025.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.